×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
NASDAQ:INGN

Inogen (INGN) Stock Forecast, Price & News

$25.86
+0.80 (+3.19%)
(As of 05/26/2022 04:00 PM ET)
Add
Compare
Today's Range
$25.28
$25.95
50-Day Range
$22.88
$35.28
52-Week Range
$22.51
$82.35
Volume
145,234 shs
Average Volume
190,357 shs
Market Capitalization
$590.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.01
30 days | 90 days | 365 days | Advanced Chart
Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

Inogen logo

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INGN
Fax
N/A
Employees
1,021
Year Founded
N/A

Sales & Book Value

Annual Sales
$358 million
Cash Flow
$0.70 per share
Book Value
$15.69 per share

Profitability

Net Income
$-6.33 million
Pretax Margin
-0.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,856,000
Market Cap
$590.54 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/26/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

346th out of 1,424 stocks

Surgical Appliances & Supplies Industry

11th out of 30 stocks

Analyst Opinion: 3.2Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Inogen (NASDAQ:INGN) Frequently Asked Questions

Is Inogen a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Inogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View analyst ratings for Inogen
or view top-rated stocks.

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Inogen
.

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) released its earnings results on Thursday, May, 5th. The medical technology company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.15. The medical technology company had revenue of $80.39 million for the quarter, compared to analyst estimates of $76.56 million. Inogen had a negative net margin of 5.64% and a negative trailing twelve-month return on equity of 3.83%. Inogen's quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) earnings per share.
View Inogen's earnings history
.

What price target have analysts set for INGN?

5 brokerages have issued 1 year price objectives for Inogen's stock. Their forecasts range from $30.00 to $47.00. On average, they anticipate Inogen's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for Inogen
or view top-rated stocks among Wall Street analysts.

Who are Inogen's key executives?
Inogen's management team includes the following people:
  • Mr. Nabil Shabshab, CEO, Pres & Director (Age 57, Pay $3.24M)
  • Ms. Alison Perry Bauerlein, Co-Founder (Age 41, Pay $621.06k) (LinkedIn Profile)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 56, Pay $558.22k)
  • Dr. Stanislav Glezer M.D., MBA, Exec. VP & CTO (Age 49, Pay $628.3k)
  • Mr. George J. Parr, Exec. VP & Chief Commercial Officer (Age 51, Pay $799.95k)
  • Ms. Kristin A. Caltrider, Exec. VP, CFO & Treasurer (Age 54)
  • Mr. Matthew James Bacso C.F.A., Investor Relations & Corp. Devel. Mang.
  • Mr. Jason Somer, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Mr. Matthew Pigeon, Investor Relations Officer
What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen CEO Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among Inogen's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.68%), Vanguard Group Inc. (11.23%), State Street Corp (3.86%), Dimensional Fund Advisors LP (2.19%), Renaissance Technologies LLC (1.47%) and Federated Hermes Inc. (1.03%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends for Inogen
.

Which major investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., State Street Corp, Goldman Sachs Group Inc., BlackRock Inc., Prudential Financial Inc., Acadian Asset Management LLC, Invesco Ltd., and Dimensional Fund Advisors LP. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Holdings A/S Novo, Ray Benjamin M Anderson, and Raymond Huggenberger.
View insider buying and selling activity for Inogen
or view top insider-selling stocks.

Which major investors are buying Inogen stock?

INGN stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Walthausen & Co. LLC, Landscape Capital Management L.L.C., Renaissance Technologies LLC, Vanguard Group Inc., Meros Investment Management LP, Envestnet Asset Management Inc., and Mitsubishi UFJ Asset Management UK Ltd..
View insider buying and selling activity for Inogen
or or view top insider-buying stocks.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $25.86.

How much money does Inogen make?

Inogen has a market capitalization of $590.54 million and generates $358 million in revenue each year. The medical technology company earns $-6.33 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Inogen have?

Inogen employs 1,021 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at (805) 562-0500 or via email at [email protected].

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.